Neurogene Q2 FY26 net loss widens to USD 34.49 million

Reuters2026/08/11 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Neurogene posted a Q2 net loss of USD 34.49 million, widening from USD 22.02 million a year earlier.
RD costs rose to USD 25.47 million from USD 19.37 million, driven by higher NGN-401 clinical and CMC spending.
GA expense climbed to USD 11.2 million from USD 6.72 million on higher stock-based compensation and pre-commercial activity.
Cash, cash equivalents and short-term investments totaled USD 225.4 million at June 30; pro forma liquidity was about USD 360.2 million post-offering.
NGN-401 Phase 1/2 data showed 100% of participants improved on CGI-I; Embolden topline data are expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608110730BIZWIRE_USPR_____20260811_BW540370) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Neurogene Q2 FY26 net loss widens to USD 34.49 million

You may also like

Crypto prices